The German pharmaceutical-and-chemicals company on Tuesday said it appointed Jean-Charles Wirth as new chief executive of life science. Wirth succeeds Matthias Heinzel, who decided to not renew his ...

Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years, Eli Lilly has been a fairly safe bet to ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Stock fragility, a measure of a company’s daily share-price move relative to its recent volatility, is on track to reach its ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

CEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven primarily by hematology sales, and an adjusted EBITDA margin of 34%. He noted strong demand for Altuvoct and Vonjo, with Altuvoct ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...